NCT04601584 2024-03-06GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLAO GENERIUMPhase 1/2 Recruiting36 enrolled
NCT01386580 2015-01-22An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.BBB-Therapeutics B.V.Phase 1/2 Completed84 enrolled